Canada Prothrombin Complex Concentrate (PCC) Market Outlook

canada's prothrombin complex concentrate (pcc) market is set to witness an upswing in 2018 with increasing demand for anticoagulants and high rates of thrombotic disorders in the country. marketsandmarkets projects a 14.6% cagr in the market from 2018 to 2032. one of the major drivers of pcc market growth in canada is the rising number of cases of thromboembolism and thrombotic disorders in the country. this is a result of growing geriatric population, increasing incidence of cardiovascular and venous thromboembolic complications, and rising prevalence of obesity and diabetes. the use of prothrombin complex factor concentrates in the clotting cascade has been found to be effective in treating patients with disseminated intravascular coagula (dic) related to thrombosis or hemorrage. the introduction of new gene-based therapies and advances in cell-based technologies utilizing patient's own cells to treat coagulopathies could further drive growth in the canadian pcc market. such therapies could help reduce the cost and improve the efficacy of treatment, benefitting both clinicians and patients. the rising cost of pcc-based therapies is a major challenge for the market. high cost of the product coupled with high cost of treatment can be a major impediment for those seeking treatment in the private healthcare sector. to overcome this challenge, the provincial government provides reimbursement cover for certain pcc-based treatments administered in the country. with the canadian healthcare system paying greater attention to blood disorders, and increased awareness of the benefits of pcc-based therapies, market prospects in the country look promising. the increasing number of clinical trials studying the efficacy of pcc-based therapies and their potential for treating thrombotic disorders could further lead to increased demand in the near future.